Form 4: Jazz Pharmaceuticals Director Patrick Enright Reports Stock Transactions
SEC Form 4
Director Patrick Enright reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.
Summary
- On August 2, 2024, Director Patrick Enright engaged in transactions involving Jazz Pharmaceuticals plc ordinary shares.
- Enright acquired 3,731 ordinary shares at a price of $0.0.
- Following the reported transactions, Enright directly owns 24,677 ordinary shares.
- Enright also holds restricted stock units which will vest in full on July 25, 2025, representing a contingent right to receive one ordinary share per unit.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Future Outlook
The restricted stock units will vest in full on July 25, 2025, subject to continuous service and certain additional conditions.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of a company director.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of stock transactions (acquisition and disposal of ordinary shares). |
| 08/06/2024 | Date of report submission. |
| 07/25/2025 | Vesting date for restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.